Multiple myeloma. Practical aspects regarding diagnosis and treatment
Journal Title: OncoReview - Year 2011, Vol 1, Issue 1
Abstract
Practical aspects of multiple myeloma diagnosis and treatment has been discussed. Myeloma diagnosis should be supported with immunoglobulin’s isotype and serum free light chain immunoglobulins studies. It is particularly important in non- or oligosecretory mullti (ple myelomas patients. Bone marrow flow cytometry and immunohistochemistry bone marrow studies with monoclonal antibodies against CD38, CD138, CD19, CD-20, CD56 and light chain staining should be performed. Treatment of patients which who are candidates for treatment with high dose therapy with autologous bone marrow transplantation should consist of cyclophosphamide, thalidomide and dexamethasone (CTD) chemotherapy, less commonly treatment with bortezomide/dexamethasone should be considered. Patients not stratified to high dose therapy should receive chemotherapy consists of melphalan, prednisone, thalidomide (MPT) or attenuated (CTDa) chemotherapy. Second line treatment includes bortezomib containing regimens. Most commonly bortezomib/dexamethasone chemotherapy has been used. Primary resistant myelomas patients should receive ESHAP (etoposdide, methyprednisolone, cis-platin, cytosine arabinoside) chemotherapy followed by autologous bone marrow transplantation, or early usage bortezomib containing regimens. High risk myeloma’s patients are treated in United Stated with inductive therapy as patients planned for high dose chemotherapy followed by autologous bone marrow transplantation followed by lenalidomide or lenalidomide/dexamethasone therapy, early bortezomibe containing regfimens induction’s protocols followed by high dose therapy or high dose therapy followed by miniallotransplantation (reduce intensity conditionning allotransplantation).
Authors and Affiliations
Andrzej Pluta
Keywords
Related Articles
- EP ID EP53092
- DOI -
- Views 264
- Downloads 0
Zastosowanie markerów molekularnych w diagnostyce zmian ogniskowych w tarczycy – współczesny stan wiedzy
Choroba guzkowa tarczycy jest powszechnie występującym schorzeniem, dotyka ona ok. 20% dorosłych w populacji polskiej. Ponieważ metody obecnie stosowane rutynowo w ocenie tych zmian często nie pozwalają na jednoznaczne r...
The effect of lipegfilgrastim on hematopoietic reconstitution and supportive treatment after megachemotherapy with autologous peripheral blood stem cell transplantation in patients with lymphoproliferative malignancies
Megachemotherapy with autologous peripheral blood stem cell transplantation (auto-PBSCT) is a standard treatment option in patients below 70 years of age with multiple myeloma (MM) as well as with relapsed and refractory...
Znaczenie inhibitorów aromatazy w leczeniu chorych na raka piersi
Leczenie hormonalne raka piersi ma na celu ograniczenie oddziaływania endogennych estrogenów na komórki nowotworu. Odkrycie receptorów hormonalnych i poznanie ich znaczenia umożliwiło zastosowanie hormonoterapii w celowa...
Spotkanie z człowiekiem. Co ja mogę z tego mieć?
Coraz częściej na konferencjach onkologicznych pojawiają się osoby reprezentujące głos pacjentów. Pragną one zwrócić naszą uwagę na inne niż medyczne aspekty choroby nowotworowej. Powinniśmy pamiętać, jak ważne jest w na...
Advanced skin melanoma – systemic treatment
In Poland, morbidity and mortality rates for melanoma are constantly increasing. In the case of inoperable disease or distant metastases, prognosis remains poor. For many years, dacarbazine has been the gold standard in...